Corporate Profile

lab_2

Using our large scale polymerase chain reaction (PCR) based manufacturing platform, we manufacture large quantities of linear DNA for various markets. Whether for supply chain security, brand protection, law enforcement or drug candidate or biologic applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success.

With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our SigNature® molecular tag technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength. Under our wholly owned subsidiary, LineaRx, Inc. (LRx), we supply DNA for use in the in vitro medical diagnostics, preclinical biotechnology and preclinical drug and biologic development and manufacturing markets. We are also engaged in preclinical and animal drug candidate development directly and with collaborators focusing on therapeutically relevant DNA constructs manufactured via our PCR-based DNA production platform.

Management Team

James A. Hayward, Phd., Sc.D

James Hayward

Chairman of the Board, President and Chief Executive Officer

Beth Jantzen

JantzenBeth

Chief Financial Officer

Judy Murrah

Judy Murrah, Chief Information Officer

Chief Information Officer

Stock Information

 

Applied DNA Sciences, Inc.
50 Health Sciences Drive
Stony Brook, NY 11790
investor@adnas.com | 631.240.8800

Sanjay M. Hurry
LHA Investor Relations
shurry@lhai.com | 212-838-3777

American Stock Transfer and Trust Company
6201 15th Ave.
Brooklyn, New York 11219
Tel: 718.921.8210
Fax: 718.921.8355
http://www.amstock.com/main/

For additional information, please click here.

Brian Kinstlinger, CFA
Alliance Global Partners
allianceg.com

Jason McCarthy, Ph.D.
Maxim Group
www.maximgrp.com

Important Note

Applied DNA Sciences. Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Applied DNA’s performance made by the analyst(s) are theirs alone and do not represent opinions, forecasts or predictions of Applied DNA or its management. Applied DNA does not by its reference above imply its endorsement of or concurrence with such information, conclusions or recommendations. This list includes analyst(s) currently known by Applied DNA to follow the company, but may not be complete and may change as firms add or delete coverage. Applied DNA does not undertake any duty to update this information or any information provided by third parties.
Merrill Kraines
Pepper Hamilton LLP
New York Times Building
620 Eighth Avenue/37th Floor
New York, New York 10018-1405
Phone: 212-808-2711
krainesm@pepperlaw.com
.
Applied DNA Sciences is not able to purchase shares on your behalf, and it is not possible for you to purchase shares directly from us. Please contact a stockbroker, bank, or independent financial advisor, who should be able to act on your behalf.

To view our SEC filings, please click here.

Marcum LLP
10 Melville Park Road
Melville, NY 11790
tel: 631 414 4000
fax: 631 414 4001
http://www.marcumllp.com

The statements made by Applied DNA on this website may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of net losses, limited financial resources,  limited market acceptance, the uncertainties inherent in research and development, future clinical data analysis including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Newsroom

Applied DNA Signs Term Sheet with TheraCann International for Exclusive License of CertainT Platform in Legal Cannabis and Hemp
Applied DNA Reports Fiscal First Quarter 2019 Financial Results
Joint Applied DNA/TheraCann’s Cannabis Seed-to-Sale Solution Positioned Towards Europe, Africa and Asia Markets by Israel Cannabis (iCAN)
Applied DNA Appoints Stephen Birkhold to the Strategic Advisory Board
Applied DNA Signs MOU with Tex-Ray Industrial to Introduce CertainT® Authentication Platform to Global Textile Brands
Applied DNA Signs Memorandum of Understanding with Sun Chemical Supply Company to Bring CertainT® Authentication Platform to Textile Manufacturers in Asia
Applied DNA Announces Closing of $2.75 Million Public Offering of Common Stock and Warrants
Applied DNA Announces Pricing of $2.75 Million Offering of Common Stock and Warrants

Events and Presentations

IR Calendar

February 7, 2019 at 4:30pm EST | Applied DNA Sciences Fiscal First Quarter 2019 Conference Call | Stony Brook

Dial-In (Toll Free): 1-844-887-9402
International Dial-In: 1-412-317-6798
Canada Toll Free Dial-In: 1-866-605-3852

*Please ask to be joined into the Applied DNA Sciences call

Live/Archived Webcast Registration: https://services.choruscall.com/links/apdn190207.html

Conference Replay Information (available 1hr after the call ends)

Replay Access Code: 10127851
Replay Dial-In (Toll Free): 1-877-344-7529
International Replay Dial-In: 1-412-317-0088
Canada Toll Free Replay Dial-In: 855-669-9658

APDN Feb 2019 Investor Call
Transcript

December 7, 2018 at 9:00am EST | Long Island Capital Alliance’s Cannabis Capital Forum | Melville, NY

LICF-Dec-Presentation

December 6, 2018 at 12:00pm EST | LineaRx Analyst Day | Stony Brook, NY

Participant Dial-in: 1-844-887-9402
Participant Dial-in (International): 1-412-317-6798
Live Webcast Link: https://services.choruscall.com/links/apdn181206.html

Replay (available 1hr after the conclusion of the live call through December 13, 2018)

Participant Dial-In: 1-877-344-7529
Participant Dial-In (International): 1-412-317-6798
Webcast Replay Link: https://services.choruscall.com/links/apdn181206.html

Presentation: LineaRx Analyst Day Technical Deck

August 13, 2018 | Applied DNA Sciences Fiscal Third Quarter 2018 Conference Call | Stony Brook, NY

Participants Conference Call Information

Dial-in: 1-844-887-9402

International Dial-in: 1-412-317-6798

* Please ask to be joined into the Applied DNA Sciences call

Live/Archived Webcast Registration: https://services.choruscall.com/links/apdn180809.html

Conference Replay Information (available 1hr after call ends)

Replay Access Code: 10122259

Dial-in: 1-877-344-7529 or +1 412-317-0088

Investor Call Presentation
Investor Call Script

May 3, 2018 | Applied DNA Sciences Fiscal Second Quarter 2018 Conference Call | Stony Brook, NY

Participants Conference Call Information

Dial-in: 1-844-887-9402

International Dial-in: 1-412-317-6798

* Please ask to be joined into the Applied DNA Sciences call

Live/Archived Webcast Registration: https://services.choruscall.com/links/apdn180503.html

Conference Replay Information (available 1hr after call ends)

Replay Access Code: 10119469

Dial-in: 1-877-344-7529

International Dial-in: 1-412-317-0088

International Codes Dial-in Link: https://services.choruscall.com/ccforms/replay.html

*Replay End Date: May 4, 2018

Investor Call Presentation

March 11-13, 2018 | ROTH Capital Markets’ 30th Annual Conference | Dana Point, CA

February 27, 2018, 10AM EST – 2018 Annual Meeting of Stockholders – Stony Brook, NY

2018 Annual Meeting of Stockholders Presentation

2018 Annual Meeting Video Bundle

Note: Replay access available until 5pm ET on Friday, March 9, 2018.

Replay Dial-in(Toll Free):  1-877-344-7529
International Replay (Toll):  1-412-317-0088

February 8, 2018 |Applied DNA Sciences Fiscal 2018 First Quarter Financial Results| Stony Brook, N.Y.

August 10, 2017 | Applied DNA Sciences Fiscal Third Quarter 2017 Conference Call | Stony Brook, NY

Archived webcast of earnings conference call (audio and slide presentation): https://services.choruscall.com/links/apdn170810.html

June 6, 2017 | LD Microcap Conference | Los Angeles, NY

March 8, 2017 | Applied DNA Sciences Annual Meeting of Stockholders | Stony Brook, NY

Online Investor Kit

Corporate Governance

Board of Directors

Applied DNA’s Board of Directors consists of individuals with proven leadership skills, broad management experience in established companies, and their reputation as independent thinkers.

With experience in fields ranging from Bioagriculture to Zoology, the company will continue to benefit from the Board’s diversity of experience and opinions.

James A. Hayward, Phd., Sc.D

Chairman of the Board, President and Chief Executive Officer

John Bitzer III

Chair of Audit Committee; Member of Compensation and Nominating Committees

Bob Catell

Joseph Ceccoli

Compensation Committee Member

Dr. Charles Ryan

Audit Committee Member

Betsy Schmalz

Dr. Yacov Shamash

Chair of Compensation and Nominating Committees; Audit Committee Member

Dr. Sanford R. Simon

Nominating Committee Member